ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

707
Analysis
Health Care • China
Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.
more
•17 Jul 2026 15:46

Hong Kong Buybacks Weekly (Jul 17th): Xiaomi, J&T Express, Gcl Technology

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Logo
122 Views
Share
•14 Sep 2021 04:33

Asia Ex-Japan Positioning:  India & Tech at Record Highs

In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.

Logo
394 Views
Share
•11 Jul 2021 08:52

China Healthcare Weekly (July.9)

The article analyzed the new policy about R&D of anti-tumor drugs based on clinical value, construction of high-quality medical service system, and...

Logo
438 Views
Share
•29 Jun 2021 09:32

EM Underweight Hits Record High Among Global Managers

Active Global managers are running record underweights in Emerging Market stocks.  The average Emerging Markets allocation sits underweight -4.56%...

Logo
294 Views
Share
•26 Jun 2021 22:06

Global Emerging Markets Weekly: 25 June 2021

This insight provides a summary of the key news developments impacting the largest countries and constituents of the Global Emerging Markets equity...

Share
x